Intranasal delivery of M2 macrophage-derived soluble products reduces neuropsychological deficit in patients with cerebrovascular disease: a pilot study

Ekaterina Shevela; Marina Davydova; Natalia Starostina; Alexandra Yankovskaya; Alexandr Ostanin; Elena Chernykh

doi:10.26599/JNR.2019.9040010

Journal of Neurorestoratology 2019, 7(2): 89-100 https://doi.org/10.26599/JNR.2019.9040010

Research Article |

Open Access | Issue | Published: 22 July 2019

Intranasal delivery of M2 macrophage-derived soluble products reduces neuropsychological deficit in patients with cerebrovascular disease: a pilot study

Show Author's Information Hide Author's Information Ekaterina Shevela(

), Marina Davydova, Natalia Starostina, Alexandra Yankovskaya, Alexandr Ostanin, Elena Chernykh

Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia

Keywords:

chronic cerebrovascular disease, intranasal therapy, M2-macrophages, cytokines, neurological improvement

Cite this article:

Shevela E, Davydova M, Starostina N, et al. Intranasal delivery of M2 macrophage-derived soluble products reduces neuropsychological deficit in patients with cerebrovascular disease: a pilot study. Journal of Neurorestoratology, 2019, 7(2): 89-100. https://doi.org/10.26599/JNR.2019.9040010

Download citation

EndNote(RIS)

BibTeX

553

Views

Downloads

Citations

Crossref

WoS

Scopus

N/A

CSCD

Abstract Full text About this article

Abstract

Objective:

We assessed the safety and clinical effectiveness of intranasal therapy with M2 macrophage-derived soluble products (M2-SPs) for treating patients with cerebrovascular disease (CVD).

Materials and methods:

The protocol of the study was registered at www.ClinicalTrails.gov (NCT02957123). The study group comprised 30 patients with chronic CVD. Neurological status was examined before therapy and at 1- and 6-month follow–up. Concentrations of 32 cytokines in the blood serum were evaluated before and 1 month after therapy onset. Neurological assessment was conducted with the following scales: Subjective Assessment of Clinical (neurological) Symptoms (SACS), Hospital Anxiety and Depression Scale (HADS), Functional Mobility Assessment in Eldery Patients (FMA), and Montreal Cognitive Assessment (MoCa).

Results:

M2-SPs treatment (once daily for 28~30 days) was found to be safe and well tolerated. Neuropsychological improvements showed the amelioration of neurological symptoms, reduction in anxiety and depression levels, improvement in balance and gait ability as well as cognitive functions. Clinical effects could be detected at the end of treatment course and was stable during 6-month follow-up. Blood serum cytokine evaluation demonstrated diminished baseline levels of many cytokines including those with neurotrophic activity (brain-derived neurotrophic factor, BDNF; hepatocyte growth factor, HGF; migration inhibitory factor, MIF). Upon treatment, most pronounced clinical responses were observed in patients with most severe cytokine deficiency and post-therapy normalization of MIF and HGF levels.

Conclusion:

Intranasal therapy with M2-SPs is safe and according to preliminary data reduces neuropsychological deficit in patients with chronic CVD. The positive effect of M2-SPs treatment seems to be HGF- and MIF-dependent.

Full text

Abstract

Full text

Outline

About this article

Intranasal delivery of M2 macrophage-derived soluble products reduces neuropsychological deficit in patients with cerebrovascular disease: a pilot study

Show Author's information Hide Author's Information Ekaterina Shevela(

), Marina Davydova, Natalia Starostina, Alexandra Yankovskaya, Alexandr Ostanin, Elena Chernykh

Research Institute of Fundamental and Clinical Immunology, Novosibirsk, Russia

Abstract

Objective:

We assessed the safety and clinical effectiveness of intranasal therapy with M2 macrophage-derived soluble products (M2-SPs) for treating patients with cerebrovascular disease (CVD).

Materials and methods:

Results:

Conclusion:

Keywords: chronic cerebrovascular disease, intranasal therapy, M2-macrophages, cytokines, neurological improvement

References(46)

[1]

Donnelly DJ, Popovich PG. Inflammation and its role in neuroprotection, axonal regeneration and functional recovery after spinal cord injury. Exp Neurol. 2008, 209(2): 378-388.

DOI Google Scholar

[2]

Hohlfeld R, Kerschensteiner M, Meinl E. Dual role of inflammation in CNS disease. Neurology. 2007, 68(22 Suppl 3): S58-S63; discussion S91–6.

DOI Google Scholar

[3]

Kerschensteiner M, Gallmeier E, Behrens L, et al. Activated human T cells, B cells, and monocytes produce brain- derived neurotrophic factor in vitro and in inflammatory brain lesions: a neuroprotective role of inflammation? J Exp Med. 1999, 189(5): 865-870.

DOI Google Scholar

[4]

Yin YQ, Cui Q, Li YM, et al. Macrophage-derived factors stimulate optic nerve regeneration. J Neurosci. 2003, 23(6): 2284-2293.

DOI Google Scholar

[5]

Gordon S, Taylor PR. Monocyte and macrophage heterogeneity. Nat Rev Immunol. 2005, 5(12): 953-964.

DOI Google Scholar

[6]

Hu XM, Leak RK, Shi YJ, et al. Microglial and macrophage polarization—new prospects for brain repair. Nat Rev Neurol. 2015, 11(1): 56-64.

DOI Google Scholar

[7]

Kigerl KA, Gensel JC, Ankeny DP, et al. Identification of two distinct macrophage subsets with divergent effects causing either neurotoxicity or regeneration in the injured mouse spinal cord. J Neurosci. 2009, 29(43): 13435-13444.

DOI Google Scholar

[8]

Wake H, Moorhouse AJ, Nabekura J. Functions of microglia in the central nervous system——beyond the immune response. Neuron Glia Biol. 2011, 7(1): 47-53.

DOI Google Scholar

[9]

Perego C, Fumagalli S, Zanier ER, et al. Macrophages are essential for maintaining a M2 protective response early after ischemic brain injury. Neurobiol Dis. 2016, 96: 284-293.

DOI Google Scholar

[10]

London A, Cohen M, Schwartz M. Microglia and monocyte- derived macrophages: functionally distinct populations that act in concert in CNS plasticity and repair. Front Cell Neurosci. 2013, 7: 34.

DOI Google Scholar

[11]

Hu XM, Li PY, Guo YL, et al. Microglia/macrophage polarization dynamics reveal novel mechanism of injury expansion after focal cerebral ischemia. Stroke. 2012, 43(11): 3063-3070.

DOI Google Scholar

[12]

Sanberg PR, Park DH, Kuzmin-Nichols N, et al. Monocyte transplantation for neural and cardiovascular ischemia repair. J Cell Mol Med. 2010, 14(3): 553-563.

DOI Google Scholar

[13]

Chernykh ER, Shevela EY, Sakhno LV, et al. The generation and properties of human M2-like macrophages: Potential candidates for CNS repair? Cell Ther Transplant. 2010, 2(6): e.000080.01.

Google Scholar

[14]

Sakhno LV, Shevela EY, Tikhonova MA, et al. The phenotypic and functional features of human M2 macrophages generated under low serum conditions. Scand J Immunol. 2016, 83(2): 151-159.

DOI Google Scholar

[15]

Chernykh ER, Shevela EY, Starostina NM, et al. Safety and therapeutic potential of M2-macrophages in stroke treatment. Cell Transplant. 2016, 25(8): 1461-1471.

DOI Google Scholar

[16]

Chernykh ER, Kafanova MY, Shevela EY, et al. Clinical experience with autologous M2 macrophages in children with severe cerebral palsy. Cell Transplant. 2014, 23(Suppl 1): S97-104.

DOI Google Scholar

[17]

Chernykh ER, Shevela EY, Kafanova MY, et al. Monocyte- derived macrophages for treatment of cerebral palsy: A study of 57 cases. J Neurorestoratology. 2018, 6: 41-47.

DOI Google Scholar

[18]

Dhuria SV, Hanson LR, Frey WH. Intranasal delivery to the central nervous system: mechanisms and experimental considerations. J Pharm Sci. 2010, 99(4): 1654-1673.

DOI Google Scholar

[19]

Galeano C, Qiu ZF, Mishra A, et al. The route by which intranasally delivered stem cells enter the central nervous system. Cell Transplant. 2018, 27(3): 501-514.

DOI Google Scholar

[20]

Alcalá-Barraza SR, Lee MS, Hanson LR, et al. Intranasal delivery of neurotrophic factors BDNF, CNTF, EPO and NT-4 to the CNS. J Drug Target. 2010, 18(3): 179-190.

DOI Google Scholar

[21]

Zhu JH, Jiang YJ, Xu GL, et al. Intranasal administration: a potential solution for cross-BBB delivering neurotrophic factors. Histol Histopathol. 2012, 27(5): 537-548.

Google Scholar

[22]

Thorne RG, Pronk GJ, Padmanabhan V, et al. Delivery of insulin-like growth factor-I to the rat brain and spinal cord along olfactory and trigeminal pathways following intranasal administration. Neuroscience. 2004, 127(2): 481-496.

DOI Google Scholar

[23]

Dewji NN, Azar MR, Hanson LR, et al. Pharmacokinetics in rat of P8, a peptide drug candidate for the treatment of alzheimer’s disease: Stability and delivery to the brain1. ADR. 2018, 2(1): 169-179.

DOI Google Scholar

[24]

Benedict C, Kern W, Schultes B, et al. Differential sensitivity of men and women to anorexigenic and memory-improving effects of intranasal insulin. J Clin Endocrinol Metab. 2008, 93(4): 1339-1344.

DOI Google Scholar

[25]

Ashpole NM, Sanders JE, Hodges EL, et al. Growth hormone, insulin-like growth factor-1 and the aging brain. Exp Gerontol. 2015, 68: 76-81.

DOI Google Scholar

[26]

Crigler L, Robey RC, Asawachaicharn A, et al. Human mesenchymal stem cell subpopulations express a variety of neuro-regulatory molecules and promote neuronal cell survival and neuritogenesis. Exp Neurol. 2006, 198(1): 54-64.

DOI Google Scholar

[27]

Lu DY, Mahmood A, Qu CS, et al. Erythropoietin enhances neurogenesis and restores spatial memory in rats after traumatic brain injury. J Neurotrauma. 2005, 22(9): 1011-1017.

DOI Google Scholar

[28]

Yang XT, Bi YY, Feng DF. From the vascular microenvironment to neurogenesis. Brain Res Bull. 2011, 84(1): 1-7.

DOI Google Scholar

[29]

Chopp M, Li Y. Stimulation of plasticity and functional recovery after stroke- cell-based and pharmacological therapy. Eur Neurol Rev. 2011, 6(2): 97.

DOI Google Scholar

[30]

Gutiérrez-Fernández M, Fuentes B, Rodríguez-Frutos B, et al. Trophic factors and cell therapy to stimulate brain repair after ischaemic stroke. J Cell Mol Med. 2012, 16(10): 2280-2290.

DOI Google Scholar

[31]

Zhang ZG, Chopp M. Neurorestorative therapies for stroke: underlying mechanisms and translation to the clinic. Lancet Neurol. 2009, 8(5): 491-500.

DOI Google Scholar

[32]

Drago D, Cossetti C, Iraci N, et al. The stem cell secretome and its role in brain repair. Biochimie. 2013, 95(12): 2271-2285.

DOI Google Scholar

[33]

Ullah I, Chung K, Oh J, et al. Intranasal delivery of a Fas-blocking peptide attenuates Fas-mediated apoptosis in brain ischemia. Sci Rep. 2018, 8(1): 15041.

DOI Google Scholar

[34]

Zhang JY, Lee JH, Gu XH, et al. Intranasally delivered wnt3a improves functional recovery after traumatic brain injury by modulating autophagic, apoptotic, and regenerative pathways in the mouse brain. J Neurotrauma. 2018, 35(5): 802-813.

DOI Google Scholar

[35]

Nakamura T, Mizuno S. The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine. Proc Jpn Acad, Ser B, Phys Biol Sci. 2010, 86(6): 588-610.

DOI Google Scholar

[36]

Hamanoue M, Takemoto N, Matsumoto K, et al. Neurotrophic effect of hepatocyte growth factor on central nervous system neurons in vitro. J Neurosci Res. 1996, 43(5): 554-564.

DOI

[37]

Miyazawa T, Matsumoto K, Ohmichi H, et al. Protection of hippocampal neurons from ischemia-induced delayed neuronal death by hepatocyte growth factor: a novel neurotrophic factor. J Cereb Blood Flow Metab. 1998, 18(4): 345-348.

DOI Google Scholar

[38]

Bottaro DP, Rubin JS, Faletto DL, et al. Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product. Science. 1991, 251(4995): 802-804.

DOI Google Scholar

[39]

Shimamura M, Sato N, Waguri S, et al. Gene transfer of hepatocyte growth factor gene improves learning and memory in the chronic stage of cerebral infarction. Hypertension. 2006, 47(4): 742-751.

DOI Google Scholar

[40]

Wright JW, Harding JW. The brain hepatocyte growth factor/c-met receptor system: A new target for the treatment of Alzheimer's disease. J Alzheimers Dis. 2015, 45(4): 985-1000.

DOI Google Scholar

[41]

Wright JW, Kawas LH, Harding JW. The development of small molecule angiotensin IV analogs to treat Alzheimer’s and Parkinson’s diseases. Prog Neurobiol. 2015, 125: 26-46.

DOI Google Scholar

[42]

Shohayeb B, Diab M, Ahmed M, et al. Factors that influence adult neurogenesis as potential therapy. Transl Neurodegener. 2018, 7: 4.

DOI Google Scholar

[43]

Cai JY, Hua FZ, Yuan LH, et al. Potential therapeutic effects of neurotrophins for acute and chronic neurological diseases. Biomed Res Int. 2014, 2014: 601084.

DOI Google Scholar

[44]

Zhang XJ, Chen LW, Wang YZ, et al. Macrophage migration inhibitory factor promotes proliferation and neuronal differentiation of neural stem/precursor cells through Wnt/β-catenin signal pathway. Int J Biol Sci. 2013, 9(10): 1108-1120.

DOI Google Scholar

[45]

Conboy L, Varea E, Castro JE, et al. Macrophage migration inhibitory factor is critically involved in basal and fluoxetine-stimulated adult hippocampal cell proliferation and in anxiety, depression, and memory-related behaviors. Mol Psychiatry. 2011, 16(5): 533-547.

DOI Google Scholar

[46]

Ohta S, Misawa A, Fukaya R, et al. Macrophage migration inhibitory factor (MIF) promotes cell survival and proliferation of neural stem/progenitor cells. J Cell Sci. 2012, 125(Pt 13): 3210-3220.

DOI Google Scholar

About this article

Publication history

Acknowledgements

Rights and permissions

Publication history

Received: 21 April 2019

Revised: 28 May 2019

Accepted: 20 June 2019

Published: 22 July 2019

Issue date: June 2019

Copyright

Acknowledgements

The authors are grateful to Anton Delvig for contribution to this manuscript.

Rights and permissions

This article is published with open access at http://jnr.tsinghuajournals.com